Ceramide C6-d7

Ceramide C6-d7 is the deuterium labeled Ceramide C6. Ceramide C6, a Ceramide pathway activator, is an exogenous short-chain ceramide which can induce apoptosis of multiple cancer cells[1][2][3].

Product Specifications

CAS Number

[2692624-22-7]

UNSPSC

12352211

Hazard Statement

H225, H301+H311+H331, H370

Target

Apoptosis; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis; Others

Field of Research

Cancer

Concentration

2.47 mM * 500 μL in Methanol

Purity

99.0

Solubility

10 mM in DMSO

Smiles

OC[C@@H]([C@@H](/C=C/CCCCCCCCCCC([2H])(C([2H])(C([2H])([2H])[2H])[2H])[2H])O)NC(CCCCC)=O

Molecular Formula

C24H40D7NO3

Molecular Weight

404.68

Precautions

H225, H301+H311+H331, H370

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Qiu L, et al. C6-ceramide induces salivary adenoid cystic carcinoma cell apoptosis via IP3R-activated UPR and UPR-independent pathways. Biochem Biophys Res Commun. 2020;525 (4) :997-1003.|[3]Liu L, et al. C6-ceramide treatment inhibits the proangiogenic activity of multiple myeloma exosomes via the miR-29b/Akt pathway. J Transl Med. 2020;18 (1) :298. Published 2020 Aug 3.